Email Us
View Reports

Alpha Emitter Market

Alpha Emitter Market Analysis - By Type of Radionuclide (Terbium (Tb-149), Astatine (At-211), Bismuth (Bi-212), Actinium (Ac-225), Radium (Ra-223), Lead (Pb-212) and Bismuth (Bi -213)), By Medical Application (Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors and Other Medical Applications), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Size, Share, Growth, Trends and Global Forecast to 2024

  • ID : 22331350  |  
  • Published : Feb-2019  |  
  • Region : Global  |  
  • Pages : 150   |  
  • Publisher : Mordor Intelligence

Alpha Emitter Market Size and Growth Rate:

According to the Research Report, the Global Alpha Emitter Market Size  was valued at USD  506.5 million in 2018 and is expected to Reach USD  3302.99 million in 2024, with a CAGR of 36.69% during the forecast period 2019-2024.

Alpha Emitter Market Growth Drivers and Restraints:

Factors that stimulate market growth include increased awareness of the potential benefits of targeted alpha emitter and an increasing number of patients with heart disease and cancer. Targeted cancer therapy or alpha (TAT) is gaining popularity as the prevalence of cancer and cardiovascular disease increases. Consumers are now more and more aware of the potential benefits of therapies aimed at curing such ailments. In addition, immunotherapy with radio with high efficiency short-range alpha particles is a surprising and promising therapeutic approach. The particles have an advantage in targeted therapy because of their exceptional ability to kill cells. However, regulatory requirements are an obstacle to translational research and clinical investigations.

Alpha Emitter Market Regional Presence:

Currently, North America dominates the alpha emitter market and is expected to continue to dominate it for a few more years. This region is expected to increase its market share in the future as the increase in chronic heart and neurological diseases is the main factor driving market growth in the region. In addition, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women per year. Similarly, the increase in the prevalence of cancer is forcing Canadian health professionals to make more use of radiation therapy for cancer treatment. This directly affects the growth of the alpha emitter market in the country.

Some of the Prominent Companies leading the Global Alpha Emitter Market Profiled in the Report are:

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd

Global Alpha Emitter Market – Detailed Segmentation:

Global Alpha Emitter Market - By Type of Radionuclide:

  • Terbium (Tb-149)
  • Astatine (At-211)
  • Bismuth (Bi-212)
  • Actinium (Ac-225)
  • Radium (Ra-223)
  • Lead (Pb-212)
  • Bismuth (Bi -213)

Global Alpha Emitter Market - By Medical Application:

  • Glioma
  • Melanoma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Endocrine Tumors
  • Other Medical Applications

Global Alpha Emitter Market - By Region:

  • North America

    • US
    • Canada
    • Mexico

  • Europe

    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe

  • Asia Pacific

    • China
    • Japan
    • India
    • Australia
    • South korea
    • Rest of Asia-Pacific

  • Middle East and Africa

    • GCC
    • South Africa
    • Rest of Middle East and Africa

  • South America

    • Brazil
    • Argentina
    • Rest of South America


    1. Study Deliverables
    2. Study Assumptions
    3. Scope of the Study


    1. Market Overview
    2. Market Drivers

      1. Increased Awareness about the Potential Benefits of Targeted Alpha Therapy
      2. Increasing Number of Patients with Cardiac and Cancer Ailments

    3. Market Restraints

      1. Short Half-life of Radiopharmaceuticals
      2. Stringent Regulatory Framework and Reimbursement Issues

    4. Need for High Capital Investment
    5. Porter's Five Force Analysis

      1. Threat of New Entrants
      2. Bargaining Power of Buyers/Consumers
      3. Bargaining Power of Suppliers
      4. Threat of Substitute Products
      5. Intensity of Competitive Rivalry


    1. Type of Radionuclide

      1. Terbium (Tb-149)
      2. Astatine (At-211)
      3. Bismuth (Bi-212)
      4. Actinium (Ac-225)
      5. Radium (Ra-223)
      6. Lead (Pb-212)
      7. Bismuth (Bi -213)

    2. Medical Application

      1. Glioma
      2. Melanoma
      3. Pancreatic Cancer
      4. Ovarian Cancer
      5. Thyroid
      6. Bone Metastasis
      7. Lymphoma
      8. Endocrine Tumors
      9. Other Medical Applications

    3. Geography

      1. North America

        1. US
        2. Canada
        3. Mexico

      2. Europe

        1. Germany
        2. UK
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe

      3. Asia Pacific

        1. China
        2. Japan
        3. India
        4. Australia
        5. South korea
        6. Rest of Asia-Pacific

      4. Middle East and Africa

        1. GCC
        2. South Africa
        3. Rest of Middle East and Africa

      5. South America

        1. Brazil
        2. Argentina
        3. Rest of South America


    1. Company Profiles

      1. Actinium Pharmaceutical Inc.
      2. Alpha Tau Medical Ltd
      3. Bayer AG
      4. Fusion Pharmaceuticals
      5. IBA Radiopharma Solutions
      6. RadioMedix Inc.
      7. Telix Pharmaceuticals Ltd
      8. List Not Exhaustive


Purchase this Market Research Report


Call us on : +1 888 709 8757

Drop us an email at :